Abattis Bioceuticals Corp. announced earnings results for the third quarter ended June 30, 2019. For the third quarter, the company announced sales was CAD 127,792 compared to CAD 237 a year ago. Net loss was CAD 735,658 compared to CAD 6.940 million a year ago. Basic eps - continuing operations was CAD 0 compared to basic loss per share from continuing operations of CAD 0.02 a year ago. For the nine months, sales was CAD 130,609 compared to CAD 5,902 a year ago. Net loss was CAD 2.134 million compared to CAD 23.816 million a year ago. Basic eps - continuing operations was CAD 0 compared to basic loss per share from continuing operations of CAD 0.08 a year ago.